Ross, H. J., Kozono, D. E., Urbanic, J. J., Williams, T. M., Dufrane, C., Bara, I., … Stinchcombe, T. (2020). AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Ross, Helen J., David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, et al. “AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, et al. AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Ross, Helen J., et al. “AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, Gandhi M, Schulze K, Brockman JM, Wang XF, Gao J, Vokes EE, Stinchcombe T. AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2020.